BioXcel Therapeutics (NASDAQ:BTAI) Rating Reiterated by HC Wainwright
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 269.00% from the stock’s current price. BTAI has […]
More Stories
Barclays Raises Vodafone Group Public (LON:VOD) Price Target to GBX 85
Vodafone Group Public (LON:VOD – Free Report) had its target price hoisted by Barclays from GBX 80 ($1.00) to GBX...
J Sainsbury (LON:SBRY) Price Target Raised to GBX 262
J Sainsbury (LON:SBRY – Free Report) had its price objective boosted by JPMorgan Chase & Co. from GBX 236 ($2.96)...
Restore (LON:RST) Rating Reiterated by Canaccord Genuity Group
Restore (LON:RST – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Canaccord Genuity Group in...
Young & Co.’s Brewery, P.L.C.’s (YNGA) Neutral Rating Reaffirmed at JPMorgan Chase & Co.
JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Young & Co.’s Brewery, P.L.C. (LON:YNGA – Free Report)...
JPMorgan Chase & Co. Raises Tesco (LON:TSCO) Price Target to GBX 240
Tesco (LON:TSCO – Free Report) had its price target hoisted by JPMorgan Chase & Co. from GBX 220 ($2.76) to...
Royal Bank of Canada Cuts M&G (LON:MNG) Price Target to GBX 215
M&G (LON:MNG – Free Report) had its price objective cut by Royal Bank of Canada from GBX 220 ($2.76) to...